{{Rsnum
|rsid=1531289
|Gene=KDR
|Chromosome=4
|position=55089065
|Orientation=minus
|GMAF=0.2893
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=KDR
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 8.8 | 40.7 | 50.4
| HCB | 5.8 | 27.0 | 67.2
| JPT | 8.0 | 34.5 | 57.5
| YRI | 14.3 | 49.0 | 36.7
| ASW | 14.0 | 36.8 | 49.1
| CHB | 5.8 | 27.0 | 67.2
| CHD | 1.8 | 26.6 | 71.6
| GIH | 14.9 | 54.5 | 30.7
| LWK | 21.8 | 59.1 | 19.1
| MEX | 6.9 | 37.9 | 55.2
| MKK | 23.1 | 53.2 | 23.7
| TSI | 8.8 | 41.2 | 50.0
| HapMapRevision=28
}}
{{PMID Auto
|PMID=19875757
|Title=Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy
}}

{{PMID|20019880|OA=1
}} Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration.

{{PMID|20959405}} The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia.

{{PMID Auto
|PMID=23030506
|Title=SINGLE NUCLEOTIDE POLYMORPHISM AND SERUM LEVELS OF VEGFR2 ARE ASSOCIATED WITH AGE RELATED MACULAR DEGENERATION
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}